Anti-human proacrosin antibody inhibits the zona pellucida (ZP)-induced acrosome reaction of ZP-bound spermatozoa

The anti-acrosin monoclonal antibody AcrC5F10 inhibited proacrosin activation, proacrosin-human zona pellucida glycoprotein A (ZPA) binding, and the zona pellucida (ZP)-induced acrosome reaction of the ZP-bound spermatozoa but had no significant effect on sperm-ZP binding. These results suggest that proacrosin-acrosin may play an important role in the ZP-induced acrosome reaction of spermatozoa after primary binding to the ZP. (Fertil Steril® 2010;93:2456–9. ©2010 by American Society for Reproductive Medicine.)

Key Words: Human, fertilization, spermatozoa, oocyte, proacrosin, acrosin, antibodies, acrosome reaction

Acrosin (EC 3.4.21.10) is a multifunctional protein localized to the acrosome of spermatozoa as the inactive zymogen proacrosin, converted to the active trypsin-like enzyme, and released during the acrosome reaction (AR) (1-3). Proacrosin activation involves endoproteolytic cleavage at both the N- and C-termini of the 53 KDa protein moiety, giving rise to the 35 KDa enzymatically active form, β -acrosin (4–6). Among the components that modulate proacrosin processing, boar zona pellucida (ZP) glycoproteins were reported to stimulate its conversion to β -acrosin (7–9). Evidence from studies done in animal experimental models and humans suggests the involvement of the proacrosin-acrosin system

Carolina Veaute, Ph.D.a De Yi Liu, Ph.D.^b Laura I. Furlong, Ph.D.a Juan C. Biancotti, Ph.D.a H. W. G. Baker, M.D., Ph.D. Mónica H. Vazquez-Levin, Ph.D.^a

- ^a Instituto de Biología y Medicina Experimental (IBYME), National Research Council of Argentina (CONICET), Buenos Aires, Argentina
- ^b Department of Obstetrics and Gynaecology, Royal Women's Hospital, University of Melbourne, Melbourne, Victoria, Australia

Received March 17, 2009; revised July 21, 2009; accepted August 12, 2009; published online October 21, 2009.

- C.V. has nothing to disclose. D.Y.L. has nothing to disclose. L.I.F. has nothing to disclose, J.C.B. has nothing to disclose, H.W.G.B. has nothing to disclose. M.H.V.-L. has nothing to disclose.
- Supported by the Agencia Nacional de Promoción de la Ciencia y Tecnología (ANPCyT, PICT2000 and PICT2004) to M.H.V.-L., and the National Health and Medical Research Council of Australia (Grant No. 400069) to D.Y.L. and H.W.G.B.
- The present address for Dr. Veaute is Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Ciudad Universitaria, Paraje El Pozo, C.C. 242, S3000ZAA, Santa Fe, Argentina. The present address for Dr. Furlong is Research Unit on Biomedical Informatics (GRIB), IMIM, UPF, PRBB, c/Dr, Aiguader 88, E-08003 Barcelona,

Reprint requests: Mónica H. Vazquez-Levin, Ph.D., Instituto de Biología y Medicina Experimental, Vuelta de Obligado 2490, Rooms B16 and B24, 1428ADN, Buenos Aires, Argentina (FAX: 54-11-4786-2564; E-mail: mhvaz@dna.uba.ar).

in several steps of fertilization, particularly in limited proteolysis and the release of other acrosomal contents during the AR, as well as in the interaction with ZP glycoproteins (10-12). Proacrosin-acrosin-deficient mouse spermatozoa generated by homologous recombination were found to have delayed ZP penetration and fertilization, they did not fertilize oocytes if challenged with wild-type spermatozoa, and they had a poor performance when exposed to oocytes with hardened ZP (13-15). In addition, Acr-/- spermatozoa showed an impairment in the release of their acrosomal proteins during the AR in spite of normal membrane vesiculation (16). Altogether, these results favor the notion of the involvement of proacrosin-acrosin in events that follow primary sperm binding to ZP.

Specifically regarding the human proacrosin-acrosin system, biochemical and molecular studies have been done to characterize structural and functional aspects of the active enzyme and the mechanism of the proenzyme activation with use of the purified proacrosin and whole sperm protein extracts (5, 6). Regarding its ability to interact with ZP glycoproteins, studies from our group performed with recombinant proacrosin (Rec-40) and truncated fragments revealed a key contribution of the sequence between positions 300-402 (DIII) to the interaction with ZP components (17), a region subjected to enzymatic processing during proenzyme activation (4, 6). Recently, our group also reported the detection of antibodies toward the human proacrosin-acrosin system in women consulting for infertility. Some of the antibodies specifically recognized the C-terminal protein region and inhibited the interaction between Rec-40 and rec-human zona pellucida glycoprotein A (hZPA), as well as the proenzyme activation (18); however, no further studies could be done to test their ability to block sperm-oocyte interaction because these antibodies are polyclonal in nature. The monoclonal antibody AcrC5F10 was developed toward human sperm proacrosin and was found to recognize the proenzyme only in acidic protein sperm extracts (6). In addition, AcrC5F10 was found to specifically recognize the recombinant proenzyme but not C-termini truncated products, and epitope mapping by the SPOTscan method identified the sequence spanning residues 305-309 (LPWYFQ) of the C-terminal region of human proacrosin (19).

On the basis of these findings, we proposed that interaction of human proacrosin with ZP glycoproteins, mainly hZPA, triggers

or accelerates the proenzyme activation, and the active enzyme participates in ZP-induced sperm AR. The AcrC5F10 antibody may inhibit binding of human proacrosin to ZPA and proenzyme activation, resulting in an impaired sperm AR that would be evidenced by a decreased number of ZP-induced acrosome-reacted spermatozoa without changes in the number of sperm cells bound to the ZP. To test this hypothesis, the present study was carried out to assess the effects of AcrC5F10 anti-acrosin antibody on [1] h-proacrosin activation and enzymatic activity in sperm extracts, [2] interaction of recombinant h-proacrosin Rec-40 with rec-hZPA, [3] human sperm-ZP binding, and [4] ZP-induced AR of ZP-bound spermatozoa.

Unless specified, chemicals were purchased from Sigma Chemical Co. (St. Louis, MO), BioRad (Richmond, CA), Qiagen (Hilden, Germany), and Invitrogen Life Technologies (Carlsbad, CA). The monoclonal antibody AcrC5F10 was purchased from Biosonda (Santiago, Chile); it has been characterized as an IgG₁ isotype specific for human acrosin by indirect immunofluorescence, ELISA, and Western immunoblotting. Recombinant human ZPA (rec-hZPA) was expressed and purified from CHO cells, as previously described (20). Recombinant h-proacrosin (Rec-40) was expressed in Escherichia coli BL21 (DE3) with use of the pET22-b expression system and was purified by preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis (19). Human semen samples were provided by normozoospermic donors according to World Health Organization standards (21). All semen samples and oocytes were obtained with the donor's written consent, and protocols including human oocytes and spermatozoa were approved by the institutional review board (Royal Women's Hospital Research and Ethic Committee). In this study, only oocytes that failed to fertilize in IVF were used. Mouse IgG₁ antibodies (product M-7894, mouse $IgG_1 \kappa$ (MOPC-21); Sigma), added at the same concentration as AcrC5F10, were used as control in all experiments.

BINDING OF REC-40 TO REC-HZPA

The effect of AcrC5F10 on binding of Rec-40 to rec-hZPA was evaluated as follows: Rec-40 (5 pmol per well) was immobilized in microtiter plates with 20 mmol/L of benzamidine, and, after blocking nonspecific binding sites, 5 μ g/mL of AcrC5F10 (test) or MOPC-21 (control) antibodies and 1.0 μ g per well of rec-hZPA were added. Binding of Rec-40 to rec-hZPA was revealed with use of a rabbit anti-hZPA antibody and an anti-rabbit IgG alkaline phosphatase conjugated secondary antibody; color reaction was developed by adding sodium p-nitrophenyl phosphate, and absorbance was measured at 450 nm (17). Experiments were repeated three times.

PROACROSIN ACTIVATION AND ACROSIN ACTIVITY

The effect of AcrC5F10 on activation of h-proacrosin or amidase activity of β -acrosin was assessed on human sperm acidic protein extracts, by adding 10 μ g/mL of AcrC5F10 (test) or MOPC-21 (control) before or after proacrosin activation, respectively, followed by evaluation of DL-BAPNA hydrolysis with use of a colorimetric assay, as previously reported (6). Evaluations were done in duplicates in protein extracts from semen samples of three different donors.

SPERM-ZP BINDING AND ZP-INDUCED AR

The effect of AcrC5F10 on human sperm-ZP binding and the ZP-induced AR of ZP-bound sperm was performed with use of unfertilized human oocytes from clinical IVF. Semen samples from normozoospermic men with normal sperm-ZP binding were used. Motile spermatozoa (2×10^6 /mL) selected by the swim-up procedure were preincubated with 5 μ g/mL of AcrC5F10 (test) or MOPC-21 (control) antibodies for 1 hour; then, four oocytes were added to both test and control sperm suspensions and incubated for an additional 2 hours. At the end of the incubation, each group of four oocytes was transferred to phosphate-buffered saline solution pH 7.4, containing 2 mg/mL bovine serum albumin, and washed by aspiration in and out of a glass pipette (inside diameter approximately 250 µm) to dislodge spermatozoa loosely adhering to the surface of the ZP. The number of spermatozoa tightly bound to the surface of the ZP of the oocytes was recorded. Then, all ZP-bound spermatozoa were removed from the ZP by vigorous aspiration in and out of a narrow-gauge micropipette with an inner diameter slightly smaller than that of the oocyte (approximately 120 μ m) and smeared in a limited area (approximately 4 mm²) of a glass slide. The acrosome status of spermatozoa was determined after cell staining with the lectin Pisum sativum agglutinin (PSA) labeled with fluorescein isothiocyanate (FITC-PSA), as follows: spermatozoa smeared onto the slide were fixed in 95% ethanol for 30 minutes after air drying and then stained in 25 μ g/mL FITC-PSA in phosphate-buffered saline solution for 2 hours; the slide was washed and mounted. Two hundred spermatozoa per sample were counted with a fluorescence microscope and oil immersion at a magnification of ×400. Spermatozoa with more than half of the head showing a brightly and uniformly fluorescent signal were scored as acrosome intact, whereas sperm cells without fluorescence (a rare pattern) or a fluorescent band at the equatorial segment were considered to be acrosome reacted. Evaluations were done in a blind fashion (22). A total of 11 experiments were carried out.


Presence of AcrC5F10 antibody during proacrosin activation resulted in a decreased protease activity when compared with the control condition (AcrC5F10 = 76% of the activity in the presence of control MOPC-21; range: 72%-78%), suggesting the ability of the AcrC5F10 to impair, to some extent, proacrosin activation. In contrast to these findings, the addition of the AcrC5F10 after activation of sperm zymogens did not affect acrosin enzymatic activity (AcrC5F10 = 97% of control; range: 95%-99%). In addition to the negative effect of AcrC5F10 on proacrosin activation, a trend toward inhibition of Rec-40 binding to rec-hZPA was also observed when AcrC5F10 was added to the protein interaction assay (range: 37%–40%, compared with 0%–5% with control antibody). When added to the gamete interaction assay, the AcrC5F10 antibody was found to have no effect on sperm binding to the ZP (number of sperm bound/ZP = 81 [median value] with AcrC5F10 and 81 with MOPC-21, Fig. 1A). Contrasting with the lack of effect on sperm-ZP binding, presence of AcrC5F10 during the gamete interaction assay was associated with a significant (P<.05; Wilcoxon paired t-test) decrease in ZP-induced AR levels of ZP-bound spermatozoa (percentage of ZP-induced acrosome-reacted spermatozoa = 34% [median] with AcrC5F10 and 52% with MOPC-21,


The results describing the ability of the AcrC5F10 antibody to inhibit proacrosin activation are in agreement with previous findings

Fertility and Sterility® 2457

FIGURE 1

Effect of AcrC5F10 on spermatozoa-ZP binding and the ZP-induced AR of ZP-bound spermatozoa. Each line represents an individual assay. Wilcoxon paired t-test was used for statistical analysis. (**A**) Average number of spermatozoa bound/ZP calculated from four oocytes for each test (mean \pm SEM; errors were omitted to diminish complexity of data representation). Differences between AcrC5F10 and control groups were not significant; P>.05. (**B**) Percentage of ZP-induced acrosomereacted spermatozoa. *P<.05.





showing that AcrC5F10 recognizes a sequence localized in the proenzyme C-terminus, a protein region subjected to processing during proacrosin activation. Moreover, they agree with a previous report describing a blocking effect of AcrC5F10 on proacrosin activation

induced by fucoidan in human sperm protein extracts (23). A rela-

tionship between abnormalities in proacrosin activation and altered

sperm performance in in vitro fertilization was previously reported by our group (24). The decrease observed in the proacrosin-ZPA binding may result from steric hindrance caused by the antibody bound to the epitope located close to some of the motifs in the proenzyme C-terminal region involved in the interaction. These findings emphasize the relevance of C-terminal region of proacrosin in binding to ZPA and in proenzyme processing to the active form.

Sperm binding to ZP was not affected by AcrC5F10 anti-acrosin antibody; these results disagree with those from a previous study in which an inhibition of sperm binding to homologous ZP by AcrC5F10 antibody was reported (23). Differences between findings of these studies may be attributed to experimental protocols (longer gamete incubation time and 100 times higher concentration of the antibody) or to causes not identified by these authors. The results on the significant inhibitory effect of the anti-acrosin antibody on the acrosome reaction are in agreement with those describing the inhibition of acrosin activity and ZP-induced AR and sperm-ZP penetration by soybean trypsin inhibitor (25). Moreover, they agree with previous reports showing an impairment on the AR by antibodies from sera of patients receiving infertility treatment (26-28) or toward other specific proteins, such as actin (29), and with recent findings from our group showing an inhibitory effect of specific anti-acrosin antibodies generated by gene immunization on calcium ionophore-induced AR of murine spermatozoa (Veaute et al., unpublished observations). The AcrC5F10 antibody appears to be unable to access proacrosin molecules in noncapacitated intact sperm cells (6); membrane vesiculation may have occurred, as described in acrosin-deficient mice (16), allowing the antibody to access the proenzyme pool stored in the acrosome and inhibiting its activation. Alternatively, access of the antibody to the acrosomal compartment also may have occurred as the result of changes on the membranes during sperm capacitation, as reported by the release of some acrosomal matrix proteins (30, 31). The AR of ZP-bound human spermatozoa is critical for sperm-ZP penetration, and disordered ZP-induced AR causes failure of fertilization in conventional IVF and severe male infertility (32).

Results of the present study have shown the inhibitory effect of the anti-acrosin antibody AcrC5F10 on both the human proacrosin-acrosin activities and the ZP-induced AR of ZP-bound human spermatozoa but no effect on sperm-ZP binding, revealing the potential detrimental effect of specific antibodies toward the protease system on fertilization. Moreover, these findings suggest that the proacrosin-acrosin system plays an important role in the initial steps of the AR of ZP-bound human spermatozoa. The identification of sperm proteins involved in different events of gamete interaction, the mechanisms of their participation, and alterations in their functions is of great relevance toward understanding the molecular basis of human fertilization, as well as to unravel the causes of infertility.

Acknowledgments: The recombinant protein hZPA was generously provided by Dr. Jeffrey Harris (Zonagen Inc., The Woodlands, TX).

REFERENCES

Tesarik J, Drahorad J, Testart J, Mendoza C. Acrosin activation follows its surface exposure and precedes membrane fusion in human sperm acrosome reaction. Development 1990;110:391–400.

Veaute. Correspondence. Fertil Steril 2010.

- Nuzzo NA, Anderson RA Jr, Zaneveld LJ. Proacrosin activation and acrosin release during the guinea pig acrosome reaction. Mol Reprod Dev 1990;25: 52–60.
- Moos J, Peknicova J, Tesarik J. Protein-protein interactions controlling acrosin release and solubilization during the boar sperm acrosome reaction. Biol Reprod 1993;49:408–15.

Veaute et al. Correspondence Vol. 93, No. 7, May 1, 2010

- Baba T, Kashiwabara S, Watanabe K, Itoh H, Michikawa Y, Kimura K, et al. Activation and maturation mechanisms of boar acrosin zymogen based on the deduced primary structure. J Biol Chem 1989:264:11920–7.
- Siegel MS, Bechtold DS, Kopta CI, Polakoski KL.
 The rapid purification and partial characterization of human sperm proacrosin using an automated fast protein liquid chromatography (FPLC) system.
 Biochim Biophys Acta 1986;883:567–73.
- Zahn A, Furlong LI, Biancotti JC, Ghiringhelli PD, Marin-Briggiler CI, Vazquez-Levin MH. Evaluation of the proacrosin/acrosin system and its mechanism of activation in human sperm extracts. J Reprod Immunol 2002;54:43–63.
- Topfer-Petersen E, Cechova D. Zona pellucida induces conversion of proacrosin to acrosin. Int J Androl 1990;13:190–6.
- Eberspaecher U, Gerwien J, Habenicht UF, Schleuning WD, Donner P. Activation and subsequent degradation of proacrosin is mediated by zona pellucida glycoproteins, negatively charged polysaccharides, and DNA. Mol Reprod Dev 1991;30:164–70.
- Lo Leggio L, Williams RM, Jones R. Some effects of zona pellucida glycoproteins and sulfated polymers on the autoactivation of boar sperm proacrosin and activity of beta-acrosin. J Reprod Fertil 1994;100:177–85.
- Urch UA, Wardrip NJ, Hedrick JL. Limited and specific proteolysis of the zona pellucida by acrosin. J Exp Zool 1985;233:479–83.
- Vazquez-Levin MH, Furlog LI, Veaute C, Ghiringhelli PD. An overview of the proacrosin/acrosin system in human spermatozoa. In: Reventós J, ed. Endocrinología molecular. Vol. 56. Barcelona: Treballs de la SCB, 2005:1–16.
- Klemm U, Muller-Esterl W, Engel W. Acrosin, the peculiar sperm-specific serine protease. Hum Genet 1991;87:635–41.
- Baba T, Azuma S, Kashiwabara S, Toyoda Y. Sperm from mice carrying a targeted mutation of the acro-

- sin gene can penetrate the oocyte zona pellucida and effect fertilization. J Biol Chem 1994;269:31845–9.
- Adham IM, Nayernia K, Engel W. Spermatozoa lacking acrosin protein show delayed fertilization. Mol Reprod Dev 1997;46:370–6.
- Nayernia K, Adham IM, Shamsadin R, Muller C, Sancken U, Engel W. Proacrosin-deficient mice and zona pellucida modifications in an experimental model of multifactorial infertility. Mol Hum Reprod 2002;8:434–40.
- Yamagata K, Murayama K, Okabe M, Toshimori K, Nakanishi T, Kashiwabara S, et al. Acrosin accelerates the dispersal of sperm acrosomal proteins during acrosome reaction. J Biol Chem 1998;273: 10470–4.
- Furlong LI, Harris JD, Vazquez-Levin MH. Binding of recombinant human proacrosin/acrosin to zona pellucida (ZP) glycoproteins. I. Studies with recombinant human ZPA, ZPB, and ZPC. Fertil Steril 2005:83:1780–90.
- Veaute C, Furlong LI, Bronson R, Harris JD, Vazquez-Levin MH. Acrosin antibodies and infertility.
 I. Detection of antibodies towards proacrosin/acrosin in women consulting for infertility and evaluation of their effects upon the sperm protease activities. Fertil Steril 2009;91:1245–55.
- Furlong LI, Hellman U, Krimer A, Tezon JG, Charreau EH, Vazquez-Levin MH. Expression of human proacrosin in *Escherichia coli* and binding to zona pellucida. Biol Reprod 2000;62:606–15.
- Harris JD, Seid CA, Fontenot GK, Liu HF. Expression and purification of recombinant human zona pellucida proteins. Protein Expr Purif 1999;16:298–307.
- World Health Organization. Laboratory manual for the examination of human semen and sperm cervical mucus interaction. 4th ed. New York: Cambridge University Press. 1999:60–1.
- Liu DY, Baker HWG. Protein kinase C plays an important role in human zona pellucida-induced acrosome reaction. Mol Hum Reprod 1997;3:1037–43.
- Moreno RD, Sepulveda MS, de Ioannes A, Barros C. The polysulphate binding domain of hu-

- man proacrosin/acrosin is involved in both the enzyme activation and spermatozoa–zona pellucida interaction. Zygote 1998;6:75–83.
- Mari SI, Rawe V, Biancotti JC, Charreau EH, Dain L, Vazquez-Levin MH. Biochemical and molecular studies of the proacrosin/acrosin system in patients with unexplained infertility. Fertil Steril 2003;79(Suppl. 3):1676–9.
- Liu DY, Baker HWG. Inhibition of acrosin activity with a trypsin inhibitor blocks human sperm penetration of the zona pellucida. Biol Reprod 1993;48:340–8.
- Mahony MC, Alexander NJ. Site of antisperm antibody action. Hum Reprod 1991;6:1426–30.
- 27. Francavilla F, Romano R, Santucci R, Marrone V, Properzi G, Ruvolo G. Interference of antisperm antibodies with the induction of the acrosome reaction by zona pellucida (ZP) and its relationship with the inhibition of ZP binding. Fertil Steril 1997;67: 1128–33.
- Feng HL, Han YB, Sparks AET, Sandlow JI. Characterization of human sperm antigens reacting with anti-sperm antibodies from an infertile female patient's serum. J Androl 2008;29:440–8.
- Liu DY, Martic M, Clarke GN, Grkovic I, Garrett C, Dunlop ME, et al. An anti-actin monoclonal antibody inhibits the zona pellucida-induced acrosome reaction and hyperactivated motility of human sperm. Mol Hum Reprod 2002;8:37–47.
- Kim KS, Gerton GL. Differential release of soluble and matrix components: evidence for intermediate states of secretion during spontaneous acrosomal exocytosis in mouse sperm. Dev Biol 2003;264:141–52.
- Wassarman PM. Mammalian fertilization: the strange case of sperm protein 56. Bioessays 2009;31:153–8.
- 32. Liu DY, Baker HW. Disordered acrosome reaction of spermatozoa bound to the zona pellucida: a newly discovered sperm defect causing infertility with reduced sperm–zona pellucida penetration and reduced in vitro fertilization. Hum Reprod 1994;9: 1694–700.

Fertility and Sterility® 2459